Edition:
United Kingdom

Ovid Therapeutics Inc (OVID.OQ)

OVID.OQ on NASDAQ Stock Exchange Global Select Market

9.72USD
15 Dec 2017
Change (% chg)

$-0.67 (-6.45%)
Prev Close
$10.39
Open
$10.21
Day's High
$10.55
Day's Low
$9.71
Volume
89,675
Avg. Vol
18,954
52-wk High
$15.70
52-wk Low
$5.28

Chart for

About

Ovid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid... (more)

Overall

Beta: --
Market Cap(Mil.): $206.16
Shares Outstanding(Mil.): 24.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 88.66 16.44
EPS (TTM): -- -- --
ROI: -- 2.36 10.62
ROE: -- 2.96 14.20

BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome

* OVID THERAPEUTICS ANNOUNCES TAK-935/OV935 HAS RECEIVED ORPHAN DRUG DESIGNATION FROM U.S. FDA FOR TREATMENT OF DRAVET SYNDROME

05 Dec 2017

BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients

* OVID THERAPEUTICS ANNOUNCES OV101 SHOWS COMPARABLE PK PROFILE IN PHASE 1 STUDY OF ADOLESCENT PATIENTS AND AMENDS PHASE 2 STARS CLINICAL TRIAL PROTOCOL TO INCLUDE ADOLESCENTS

28 Nov 2017

BRIEF-Ovid Therapeutics Q3 loss per share $0.38

* Ovid Therapeutics reports third quarter 2017 financial results and corporate progress

09 Nov 2017

BRIEF-Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935

* Ovid Therapeutics announces first patient randomized in phase 1b/2a clinical trial of TAK-935/OV935 in adults with rare epilepsies Source text for Eikon: Further company coverage:

21 Aug 2017

BRIEF-Ovid Therapeutics Q2 loss per share $0.57

* Ovid Therapeutics reports second quarter 2017 financial results and corporate progress

10 Aug 2017

Earnings vs. Estimates